IL279851A - Preparations and methods for treating diseases or conditions related to inflammasome - Google Patents
Preparations and methods for treating diseases or conditions related to inflammasomeInfo
- Publication number
- IL279851A IL279851A IL279851A IL27985120A IL279851A IL 279851 A IL279851 A IL 279851A IL 279851 A IL279851 A IL 279851A IL 27985120 A IL27985120 A IL 27985120A IL 279851 A IL279851 A IL 279851A
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- conditions
- methods
- related diseases
- inflammasome related
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/026,482 US10703811B2 (en) | 2016-12-29 | 2018-07-03 | Methods and compositions for treating multiple sclerosis |
| PCT/US2019/040635 WO2020010273A1 (en) | 2018-07-03 | 2019-07-03 | Compositions and methods for treating inflammasome related diseases or conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL279851A true IL279851A (en) | 2021-03-01 |
Family
ID=78823964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL279851A IL279851A (en) | 2018-07-03 | 2020-12-30 | Preparations and methods for treating diseases or conditions related to inflammasome |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12570735B2 (enExample) |
| EP (1) | EP3818081A4 (enExample) |
| JP (2) | JP7824030B2 (enExample) |
| KR (1) | KR20210071944A (enExample) |
| CN (1) | CN113316588B (enExample) |
| AU (1) | AU2019297515A1 (enExample) |
| BR (1) | BR112020026798A2 (enExample) |
| CA (1) | CA3105129A1 (enExample) |
| CL (1) | CL2020003447A1 (enExample) |
| CO (1) | CO2021001172A2 (enExample) |
| IL (1) | IL279851A (enExample) |
| MX (1) | MX2021000142A (enExample) |
| PH (1) | PH12020552286A1 (enExample) |
| SG (1) | SG11202013176VA (enExample) |
| WO (1) | WO2020010273A1 (enExample) |
| ZA (2) | ZA202100703B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240060995A1 (en) * | 2012-02-06 | 2024-02-22 | University Of Miami | Innate immune proteins as biomarkers for traumatic brain injury in adult and pediatric patients |
| JP2020503345A (ja) | 2016-12-29 | 2020-01-30 | ユニバーシティ オブ マイアミ | 肺におけるインフラマソーム活性及び炎症をモジュレートする方法 |
| US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
| MX2021000142A (es) | 2018-07-03 | 2021-05-12 | Univ Miami | Composiciones y metodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas. |
| EP4142705A4 (en) * | 2020-04-27 | 2024-07-03 | University of Miami | Compositions and methods for treating inflammasome related diseases or conditions |
| TW202334202A (zh) * | 2021-11-16 | 2023-09-01 | 瑞士商Ａｃ免疫有限公司 | 用於治療和診斷的新分子 |
| JP2025530202A (ja) * | 2022-09-09 | 2025-09-11 | ユニバーシティー オブ マイアミ | 神経疾患を治療するためのインフラマソーム抗体組成物及び方法 |
| WO2024114906A1 (en) * | 2022-11-30 | 2024-06-06 | Mabylon Ag | Antibodies against apoptosis-associated speck-like protein containing a card (asc) and uses thereof |
| WO2026042013A1 (en) * | 2024-08-19 | 2026-02-26 | Institute Of Molecular And Clinical Ophthalmology Basel (Iob) | Mitochondrial therapy |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2763849B1 (fr) | 1997-05-28 | 2000-09-15 | Rhone Poulenc Rorer Sa | Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US7244764B2 (en) | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| AU2005243193B2 (en) | 2004-04-29 | 2011-01-27 | Otsuka Pharmaceutical Co., Ltd. | Antibodies specific for glycoprotein VI and methods of producing these antibodies |
| JP4496214B2 (ja) * | 2004-05-17 | 2010-07-07 | 電気化学工業株式会社 | ポリ塩化ビニル繊維及びその製造方法並びに人工毛髪 |
| AU2005306997B2 (en) | 2004-10-25 | 2012-07-05 | Merck Sharp & Dohme Corp. | Anti-ADDL antibodies and uses thereof |
| TW200636064A (en) | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
| CA2623565A1 (en) | 2005-09-28 | 2007-04-05 | Biovascular, Inc. | Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation |
| RS55963B1 (sr) | 2005-12-29 | 2017-09-29 | Janssen Biotech Inc | Humana anti-il-23 antitela, kompozicije, metode i upotrebe |
| EP2447285A3 (en) | 2006-05-25 | 2013-01-16 | Momenta Pharmaceuticals, Inc. | Low molecular weight heparin composition and uses thereof |
| US20100136030A1 (en) * | 2007-02-27 | 2010-06-03 | Lamhamedi-Cherradi Salah-Eddine | Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases |
| US8685400B2 (en) | 2007-07-30 | 2014-04-01 | University Of Miami | Modulating inflammasome activity and inflammation in the central nervous system |
| EP2300000A1 (en) * | 2008-07-03 | 2011-03-30 | University of Massachusetts | Methods and compositions for reducing inflammation and treating inflammatory disorders |
| EP2145624A1 (en) | 2008-07-18 | 2010-01-20 | Sanofi-Aventis | Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment |
| EP2475380A1 (en) | 2009-09-11 | 2012-07-18 | Protaffin Biotechnologie AG | Composition for treatment of cxcl8-mediated lung inflammation |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| SMT202000095T1 (it) | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| IT1406201B1 (it) | 2010-12-10 | 2014-02-14 | Univ Degli Studi Trieste | Biomarcatori per la diagnosi della sclerosi multipla |
| WO2012123299A1 (en) * | 2011-03-11 | 2012-09-20 | Roche Diagnostics Gmbh | Asc as marker for chronic obstructive pulmonary disease (copd) |
| WO2013049278A1 (en) | 2011-09-30 | 2013-04-04 | Novartis Ag | USE OF IL-1 ß BINDING ANTIBODIES |
| CA2863417C (en) | 2012-02-06 | 2020-07-28 | University Of Miami | Innate immune proteins as biomarkers for cns injury |
| TWI480044B (zh) | 2012-03-16 | 2015-04-11 | Taichung Veterans General Hospital | A high molecular weight heparin or low molecular weight heparin for the preparation of a composition for at least two consecutive days of administration to improve the allergic constitution |
| US20140314746A1 (en) * | 2013-03-13 | 2014-10-23 | Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine | Methods for treating or preventing fibrosis in subjects afflicted with scleroderma |
| CN105209643A (zh) | 2013-05-17 | 2015-12-30 | 豪夫迈·罗氏有限公司 | 用于诊断和治疗炎性肠病的方法 |
| JP6359013B2 (ja) | 2013-07-29 | 2018-07-18 | 国立大学法人 鹿児島大学 | １，５−ｄ−アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬 |
| EP4491180A1 (en) | 2014-01-10 | 2025-01-15 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| EP3183582B1 (en) | 2014-08-18 | 2020-02-12 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Biomarkers for diagnosis and management of neuro-immunological diseases |
| WO2016059571A1 (en) | 2014-10-16 | 2016-04-21 | Novartis Ag | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis |
| US20160263183A1 (en) | 2015-03-10 | 2016-09-15 | Brown University | Methods for treating lung disease |
| CN114181281A (zh) | 2015-05-12 | 2022-03-15 | 加利福尼亚大学董事会 | 用于炎症和纤维化的肽治疗 |
| CN108349867B (zh) | 2015-08-17 | 2021-03-09 | 安成生物科技股份有限公司 | 用于抑制asc的表达、nlrp3的表达和/或nlrp3炎性复合体的形成的双醋瑞因或其类似物 |
| KR101948048B1 (ko) * | 2016-12-08 | 2019-02-14 | 한양대학교 에리카산학협력단 | 톡소포자충 ｇｒａ７ 항원 유래 재조합 단백질을 유효성분으로 포함하는 결핵 예방 또는 치료용 약학 조성물 |
| JP2020503345A (ja) | 2016-12-29 | 2020-01-30 | ユニバーシティ オブ マイアミ | 肺におけるインフラマソーム活性及び炎症をモジュレートする方法 |
| US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
| US10755739B1 (en) | 2016-12-30 | 2020-08-25 | John Fristrom | Remote railway crossing programmable device and methods thereof |
| AU2018336897A1 (en) | 2017-09-20 | 2020-04-30 | University Of Miami | Method for detecting inflammasome proteins as biomarkers of neurological disorders |
| MX2021000142A (es) | 2018-07-03 | 2021-05-12 | Univ Miami | Composiciones y metodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas. |
-
2019
- 2019-07-03 MX MX2021000142A patent/MX2021000142A/es unknown
- 2019-07-03 KR KR1020217003239A patent/KR20210071944A/ko not_active Ceased
- 2019-07-03 BR BR112020026798-8A patent/BR112020026798A2/pt unknown
- 2019-07-03 JP JP2020573110A patent/JP7824030B2/ja active Active
- 2019-07-03 AU AU2019297515A patent/AU2019297515A1/en active Pending
- 2019-07-03 CA CA3105129A patent/CA3105129A1/en active Pending
- 2019-07-03 CN CN201980056542.1A patent/CN113316588B/zh active Active
- 2019-07-03 US US17/255,653 patent/US12570735B2/en active Active
- 2019-07-03 EP EP19831331.4A patent/EP3818081A4/en active Pending
- 2019-07-03 SG SG11202013176VA patent/SG11202013176VA/en unknown
- 2019-07-03 WO PCT/US2019/040635 patent/WO2020010273A1/en not_active Ceased
-
2020
- 2020-12-29 PH PH12020552286A patent/PH12020552286A1/en unknown
- 2020-12-30 IL IL279851A patent/IL279851A/en unknown
- 2020-12-30 CL CL2020003447A patent/CL2020003447A1/es unknown
-
2021
- 2021-02-01 ZA ZA2021/00703A patent/ZA202100703B/en unknown
- 2021-02-02 CO CONC2021/0001172A patent/CO2021001172A2/es unknown
-
2022
- 2022-01-31 ZA ZA2022/01437A patent/ZA202201437B/en unknown
-
2025
- 2025-01-16 JP JP2025006393A patent/JP7850296B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3818081A4 (en) | 2022-06-22 |
| EP3818081A1 (en) | 2021-05-12 |
| JP7824030B2 (ja) | 2026-03-04 |
| ZA202201437B (en) | 2024-05-30 |
| ZA202100703B (en) | 2022-08-31 |
| WO2020010273A1 (en) | 2020-01-09 |
| CL2020003447A1 (es) | 2021-07-30 |
| US12570735B2 (en) | 2026-03-10 |
| SG11202013176VA (en) | 2021-01-28 |
| PH12020552286A1 (en) | 2021-06-21 |
| JP2021528092A (ja) | 2021-10-21 |
| BR112020026798A2 (pt) | 2021-03-30 |
| CO2021001172A2 (es) | 2021-07-09 |
| US20210284723A1 (en) | 2021-09-16 |
| AU2019297515A1 (en) | 2021-02-25 |
| CN113316588B (zh) | 2025-02-28 |
| KR20210071944A (ko) | 2021-06-16 |
| JP2025067915A (ja) | 2025-04-24 |
| JP7850296B2 (ja) | 2026-04-22 |
| CN113316588A (zh) | 2021-08-27 |
| MX2021000142A (es) | 2021-05-12 |
| CA3105129A1 (en) | 2020-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298690B1 (en) | Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions | |
| ZA202100703B (en) | Compositions and methods for treating inflammasome related diseases or conditions | |
| IL273959A (en) | Methods and preparations for the treatment of rare diseases | |
| IL274702A (en) | Compounds and Methods for Neurological Diseases | |
| AU2018297285A1 (en) | Compositions and methods for treating or preventing endocrine FGF-linked diseases | |
| EP3687524A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF OPHTHALMIC DISORDERS | |
| SMT202500382T1 (it) | Composizioni per trattare e/o prevenire malattie da aggregazione proteica | |
| ZA202006234B (en) | Compositions and methods for the treatment of neurological diseases | |
| SG11202102442WA (en) | Methods and compositions for preventing and treating atherosclerosis and related diseases | |
| IL275767A (en) | Compositions and methods for treating metabolic diseases | |
| IL272937A (en) | Preparations and methods for the treatment of diseases involving fibrosis | |
| IL280413A (en) | Bismuth-thiol preparations and wound treatment methods | |
| EP3445376A4 (en) | COMPOSITIONS AND METHODS FOR IMPROVED RESTORATION AND CONSERVATION OF THE INTEGRITY OF TISSUE BARRIERS | |
| SG11202012055PA (en) | Methods and compositions for preventing or treating calciphylaxis | |
| IL269743A (en) | Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions | |
| EP3768095A4 (en) | Compositions and methods for treating diarrheal diseases | |
| EP3265103A4 (en) | Compositions and methods for treating ocular diseases | |
| IL261779A (en) | Preparations for the treatment and prevention of hoof and claw disease | |
| EP3672583A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES | |
| EP3496696A4 (en) | COMPOUNDS AND METHODS FOR TREATING THE DISEASE. | |
| EP3310338A4 (en) | Compositions and methods for treating inflammatory disease or conditions | |
| IL280262A (en) | Compositions and methods for treating cancer | |
| HK40053279A (en) | Compositions and methods for treating nrp2-associated diseases | |
| HK40021297A (en) | Compositions and methods for treating or preventing gut permeability-related disorders | |
| AU2018900992A0 (en) | Compositions and methods for treating respiratory diseases |